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1. Introduction  
ATPases are enzyme systems that originated in a common ancestor and are distributed 
universally among all organisms. There are three types of ATPases: those found in archaea 
(A-ATPases), synthases (F-APTases), and vacuole or vacuolar ATPases (V-ATPases) 
(Nelson, Nelson 1989). They are essential for life and have in common the fact that they 
create an electrochemical ion gradient across the membrane to hydrolyze or synthesize ATP. 
Structurally, they are enzymatic complexes that work as molecular rotary motors. ATPases 
are formed by two domains, a hydrophobic domain (A0, V0, and F0) and a hydrophilic 
domain (A1, V1, and F1) connected by a central axis and either one or two lateral axes. In 
this chapter, we are going to discuss V-ATPases. 
1.1 Biological functions 
Unlike F-ATPases, whose primary function in eukaryotic cells is to generate ATP from 
proton motive force, V-ATPases function exclusively as ATP-dependent proton pumps, 
performing diverse biological functions within cells (Nelson 1992; Kane 1999; Saroussi & 
Nelson 2008, Stevens & Forgac 1997). 
Regarding to the membrane transport, V-ATPases play an important role in receptor-
mediated endocytosis (Forgac 1998), intracellular transport, and the acidification of late 
endosomes (Kane 1999; Stevens & Forgac 1997; Nishi & Forgac 2002; Kawasaki-Nishi & 
Forgac 2003; Finbow, Harrison 1997). Vacuolar acidification has also been reported to be 
involved in the transport of lysosomal enzymes from the Golgi apparatus to the lysosomes 
(Stevens, Forgac 1997; Moriyama, Nelson 1989). V-ATPases appear to play an important role 
in the creation of the microenvironment needed for correct protein transport, exchange, and 
secretion (Schoonderwoert et al. 2000). 
Although V-ATPases were initially identified in intracellular compartments, knowledge on 
the roles they play in the plasma membrane has increased enormously. V-ATPases located 
at the apical membrane of type A intercalated cells are involved in the secretion of protons 
in renal fluid (Smith et al. 2005; van Hille et al. 1993). Type B intercalated cells, whose 
function is to secrete bicarbonate, also contain V-ATPases, but they are located between the 
apical and basolateral membranes (Nishi & Forgac 2002, van Hille et al. 1993). In 
macrophages and neutrophils, plasma membrane V-ATPases (pmV-ATPases) are involved 
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in the homeostasis of cytoplasmic pH (Stevens & Forgac 1997, Nishi & Forgac 2002, Nanda 
et al. 1996). These ATPases also play an important role in bone reabsorption (Marshansky, 
Futai , Stevens, Forgac 1997, Nishi, Forgac 2002, Smith et al. 2005, van Hille et al. 1993). 
Another of their functions is to regulate sperm motility and maturation on the apical 
membrane of epididymal cells and vas deferens by stabilizing the sperm medium (Nishi, 
Forgac 2002). The role of V-ATPases in cancer cells will be discussed in a specific place. 
Other additional functions of V-ATPases involves the low pH maintained by them in 
lysosomes and phagosomes, which is necessary for the activity of the degradative enzymes 
in these compartments (Sun-Wada, Wada & Futai 2003, Sun-Wada, Wada & Futai 2004, 
Kurashima et al. 1996) and the transport of small molecules and ions (Nishi, Forgac 2002, 
Kurashima et al. 1996). The driving force necessary for the accumulation of 
neurotransmitters in synaptic vesicles is proton motive force, which is generated by V-
ATPases (Nelson, Harvey 1999). The fusion-fission balance of the vacuolar system of 
eukaryotic cells is also controlled by V-ATPases, i.e. via the interaction between vacuolar 
SNARE proteins and GTPase Vps1p (Baars et al. 2007, Muller et al. 2003). Exocytosis in 
eosinophils and binding to actin cytoskeleton is also regulated by V-ATPases (Kurashima et 
al. 1996). The association between V-ATPase subunits and other cellular proteins, for 
example, that which occurs between the C subunit of the V0 domain and the E5 
oncoprotein, or between platelet-derived growth factor (PDGF) and b1 integrin, indicate 
that these subunits play a role in cell growth and transformation. V-ATPases also allow the 
entry of certain viruses (e.g. influenza) and toxins (e.g. diphtheria) into the intracellular 
space via the binding of these pathogens to the endosomal membrane (Stevens, Forgac 
1997). In the case of the human immunodeficiency virus (HIV), the association between the 
V-ATPase H subunit and the HIV-1 Nef protein, which controls the expression of CD4 (the 
main HIV receptor), facilitates endocytosis of Nef and/or alterations in the acidification of 
the endosomal pathway by this protein (Nishi, Forgac 2002)(Marshansky, Futai ). The most 
recent function attributed to V-ATPases is their involvement in the regulation of cell-cell 
fusion to form larger cells, as is the case with osteoclasts and macrophages (Wada et al. 
2008). 
1.2 V-atpase structure  
The V-ATPase proton pump has multiple subunits, each with multiple isoforms, hence the 
need for a clear, standardized nomenclature system. Initially, the HUGO Gene 
Nomenclature Committee agreed to use the ATP as the stem, or root, symbol. ATP6, for 
example, indicated ATPase, H+ transport, lysosomal (vacuolar proton pump). In 2003, the 
nomenclature system for genes encoding V-ATPase subunits was revised and it was decided 
to maintain the root ATP6 and add the domain to which a particular subunit belonged, 
followed by the letter of the subunit, and finally the number of the isoform, where relevant, 
(e.g. ATP6V1C1, ATP6V1E, etc.) (Smith A.N. et al. 2003). 
V-ATPase structure, function, biogenesis, and regulation was widely revised by Stevens and 
Forgac (Stevens & Forgac 1997). We will use the nomenclature system proposed by these 
authors to explain the structural subunits of V-ATPase together with relevant modifications 
based on recent research using transmission electron microscopy (Wilkens, Zhang & Zheng 
2005). 
V-ATPases have been found to be practically identical in terms of the composition of their 
subunits in all eukaryotic cells. They have two distinct structures: a peripheral catalytic 
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sector (V1) and a hydrophobic membrane sector (V0) responsible for driving protons 
(Gruber 2005). The catalytic sector is composed of five polypeptides known as subunits A, B, 
C, D, and E, with a molecular weight, in decreasing order, ranging from 72 to 33 kDa. Recent 
advances in knowledge of the mechanism of action of F-ATPases have clarified the 
relationship between function and structure for each of the subunits of these enzymes (Qi, 
Wang & Forgac 2007, Inoue et al. 2005) (Figure 1). 
 
 
Fig. 1. Diagram of V-ATPase. The cytosolic domain (in yellow) is formed by three A 
subunits, three B subunits, three G subunits, and one C, D, E, F, and H subunit. The V0 
transmembrane domain is formed by five subunits: a, c, c’, c’’ and d. The V1 domain 
contains the catalytic unit (Nishi & Forgac 2002).  
1.3 V-ATPase regulation 
Three major regulatory mechanisms have been described for V-ATPase: 1) the regulation of 
pump density, which allows different cells to maintain their cytoplasmic and vacuolar pH 
stable; 2) the regulation of V1 and V0 domain association/dissociation, for example, a 
decrease in glucose levels can cause a 70% dissociation of the V1 domains of the membrane; 
and 3) the regulation of secretory activity, via the maintenance of balance in the formation of 
bisulfite and binding efficiency between H+ and the pump. Other mechanisms include the 
necessary modifications in the membrane potential for the generation of electrogenic force 
(Forgac 1998; Peng, Stone & Xie 1993) and alterations in the vacuolar transporter chaperone 
(Vtc) complex, which affect the conformation of the V0 domain and its function in vacuole 
fusion of the membrane (Muller et al. 2003). 
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2. V-ATPase inhibitors 
Scientific evidence suggests that the acidic tumor microenvironment is key to managing 
cancer progression and metastasis. In particular, V-ATPases play a major role in metastasis 
tumor development because many tumor cells secrete lysosomal enzymes that participate in 
the extracellular matrix degradation necessary for metastatic invasion. These enzymes are 
most active at low optimal pH; moreover, V-ATPases are responsible for microenvironment 
acidification (Nishi, Forgac 2002, Martinez-Zaguilan et al. 1993). Among the many 
mechanisms that regulate the tumor microenvironment, V-ATPases are especially 
significant because they can be inhibited by proton pump inhibitors. (Fais et al. 2007). 
2.1 Classes of V-ATPase inhibitors 
Initial attempts to block V-ATPases were made after bafilomycin and concanamycin were 
discovered in 1988 (Bowman, Siebers & Altendorf 1988). New molecules capable of 
inhibiting V-ATPase to a greater or lesser extent via different mechanisms of action were 
later discovered. Such molecules include benzolactone enamides salicylihalamide (Erickson 
et al. 1997), lobatamide A and B (Galinis et al. 1997), apicularen (Kunze B., Janse R., Sasse F., 
Höfle G. and Reichenbach H. 1998), indolyls (Gagliardi et al. 1998, Nadler et al. 1998), 
oximidine (Kim et al. 1999), macrolactone archazolid (Sasse et al. 2003), lobatamide C (Shen 
et al. 2003), and cruentaren(Kunze et al. 2006). The latest generation of inhibitors include 
NiK12192 (Saroussi, Nelson 2008, Petrangolini et al. 2006), FR202126 (Niikura 2007), and PPI 
SB 242784 (Hesselink et al. 2008). We can see the differences and similarities of V-ATPase 
inhibitors in Table 1:  
The V-ATPase inhibitors studied most thoroughly and used most often are macrolide 
antibiotics with 18-membered lactone rings, namely, bafilomycins and concanamycins. 
Bafilomycin and concanamycin are commercially available, and various laboratories have 
developed in vitro synthesis processes for experimental purposes (Scheidt et al. 2002). The 
remaining V-ATPase inhibitors are still in experimental phase, due to possible side effects 
that may occur in humans. However, PPIs are the treatment of choice for peptic diseases 
such as gastroesophageal reflux (Larsson et al. 1985). While these pumps block the secretion 
of gastric acid, they also directly inhibit V-ATPase activity. Examples of PPIs include 
omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole (Horn 2000), all of 
which accumulate in acidic compartments (De Milito, Fais 2005a). PPI treatment has been 
associated with V-ATPase activity inhibition and an increase in both extracellular pH and 
pH in lysosomal organelles. In vivo experiments using mice/human xenografts have shown 
that pretreatment with PPIs can sensitize solid human tumors to chemotherapy drugs (De 
Milito, Fais 2005a).  
Treatment with PPIs has also been found to sensitize tumor cells to cisplatin, 5-fluoracil, and 
vinblastine through changes in cellular pH gradients, with retention of the drugs in the 
cytoplasm, and in the nucleus in the case of doxorubicin (De Milito, Fais 2005a, Luciani et al. 
2004, Luciani et al. 2004, Cianfriglia et al. 1990).  
It is also known that low pH levels are suitable for the complete activation of PPIs (De Milito 
et al. 2007), suggesting that tumor alkalinization may be an extremely interesting target for 
future anticancer treatments (De Milito, Fais 2005a, Luciani et al. 2004, De Milito, Fais 
2005b). Specific V-ATPase inhibitors such as concanamycin and bafilomycins are other 
candidates for investigation, not only to treat cancer but also to reduce MDR in tumors 
(Perez-Sayans et al. 2009, Sasazawa et al. 2009). 
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CLASSES OF V-ATPase INHIBITORS 
 Chemistry Provenience Binding site Action 
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Concanamycin
& 
Bafilomycin 
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antibiotics 
with 18-
membered 
lactone rings 
 
 
 
Streptomyces 
 
 
 
Unknown 
 
 
V-ATPases 
inhibition 
Ionophoric 
properties 
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Salicylihamide 
A 
 
 
Apicularens 
 
 
Lobatamides 
 
 
Oximidines 
 
 
Cruentaren 
Macrocyclic 
salicylate 
Sponge Haliclona 
sp. 
VO complex Animal V-ATPases 
inhibition 
Cytotoxin 
Lactone ring Chondromyces VO complex Highly toxic for 
human and animal 
cell 
Substitution of 
enamide NH, 
salicylate, and 
phenyl salicylate
 
Tunicate Aplidium 
lobatum 
 
VO complex 
 
Animal and 
mammalian V-
ATPases inhibition 
 
Lactone ring Pseudomonas sp. VO complex Animal and 
mammalian V-
ATPases inhibition 
Lactone ring Byssovorax cruenta VO complex Cytotoxicity on 
mammalian and 
fungal cells at 
mitochondrial F-
ATPases 
Archazolid Macrocyclic 
lactone ring 
with a thiazole 
side 
Archangium 
gephyra 
Cystobacter 
violaceus 
VO subunit c Cytotoxicity on 
mammalian cell line 
Indolyls Bafilomycin-
based 
Synthesis VO subunit c V-ATPase inhibitor 
Late-generation 
V-ATPase 
inhibitors 
NiK12192, SB 242784, FR202126, 3-bromopyruvate (3-Br PA), 
Tributyltin chloride (TBTCl), FR177995, FR167356 
Table 1. Classes of V-ATPase inhibitors 
3. Role of v-ATPases inhibitors in cancer 
3.1 Tumor metastasis  
The development and maintenance of the proton gradient present in tumors is due directly to 
the ability of tumor cells to secrete protons (H+) (Martinez-Zaguilan et al. 1993, McLean et al. 
2000), acidify the extracellular medium (Cardone, Casavola & Reshkin 2005, Perona, Serrano 
1988), and keep the cytosolic pH alkaline (Sennoune, Martinez-Zaguilan 2007). This ability also 
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increases with tumor aggressiveness (Montcourrier et al. 1997, Parkins et al. 1997). In addition, 
low pH may cause extracellular matrix (ECM) degradation and remodeling through activation 
of proteolytic enzymes which contribute to invasion and cancer metastasis (Martinez-Zaguilan 
et al. 1996, Rofstad et al. 2006). Proteases need low extracellular pH to optimize their 
activation, including metalloproteinases (MMP), morphogenetic bone metalloproteinases 
(protein type 1), tissue serine proteases, and adamalysin-related proteinases. Among them, 
MMPs are the proteases basically involved in degradation and remodelling of all extracellular 
matrix (ECM) structural components (Montcourrier et al. 1994, Rozhin et al. 1994, Johnson et 
al. 2000, Kato et al. 2005, Gocheva, Joyce 2007). 
Sennoune et al. assessed the effect of bafilomycin A1 in breast tumor cells and found that 
cytoplasmic pH recovery was inhibited in response to acid load, in both highly and lowly 
metastatic cells, although to a greater extent in highly metastatic cells (Sennoune et al. 2004). 
This suggests that V-ATPases in the plasma membrane are involved in the acquisition of a 
more metastatic phenotype and that the use of V-ATPase inhibitors allows distant 
metastasis to be minimized (Figure 2).  
 
 
Fig. 2. Proposed mechanism by which overexpression of pmVATPase at the leading edge of 
the cell modulates cell migration/invasion. The proposed model should be viewed as a 
framework to explain how pmV-ATPases determine the acquisition of an invasive 
phenotype needed for angiogenesis and metastasis. Changes in pHcyt are critical for 
establishing cell polarity needed for cell movement. A critical step in directed motility and 
migration is the asymmetric actin polymerization at the leading edge (Sennoune, Martinez-
Zaguilan 2007). 
www.intechopen.com
V-ATPase Inhibitors in Cancer Treatment and Their  
Implication in Multidrug Resistance in Oral Squamous Cell Carcinoma  
 
135 
Using RNA interference techniques, Lu et al. found that distant metastasis could be delayed 
and suppressed in human hepatocellular carcinoma in vitro by reducing proton extrusion 
and gelatinase activity through the inhibition of V-ATPase subunit c (ATP6L) (Lu et al. 
2005). This fact is consistent with subunit c block by bafilomycin and concanamycin, as this 
is their main binding site to V-ATPase (Bowman et al. 2004). In tyrosinase-positive 
amelanotic melanoma cells, inactive tyrosinase accumulates in the endoplasmic reticulum 
because the presence of aberrant V-ATPases blocks trafficking through secretory pathways. 
The use of V-ATPase inhibitors, such as bafilomycin A1 or concanamycin A, improves 
transport, demonstrating the involvement of this enzyme and preventing conditions that 
favor metastatic dissemination (Halaban et al. 2002). 
Hence, both in vitro or in vivo, V-ATPases are a target for anticancer therapeutic agents, 
either directly by regulating the pH gradient in the tumor environment or indirectly by 
preventing ECM protease activation (Fais et al. 2007). 
3.2 Tumor cell growth and survival  
V-ATPases may also play a significant role in tumor cell survival by regulating pH and 
preventing apoptosis. As previously reported, plasma membrane V-ATPases help regulate 
cytosolic pH in macrophages and neutrophils (Nanda et al. 1996). This mechanism may also 
be used by tumor cells, which produce more H+ due to high glycolytic activity (Gatenby, 
Gillies 2004). Treatment with V-ATPase inhibitors lowers H+ extrusion, both in vitro and in 
vivo (Volk, Albert & Kempski 1998, McSheehy et al. 2003). 
Bafilomycin A1 was assessed as a potential anticancer agent because it inhibits cell 
proliferation and tumor growth. Although this effect has been attributed to the inhibition of 
intracellular acidosis by blocking V-ATPases, the precise mechanism remains unknown 
(Bowman et al. 2004). A study conducted by Lim et al., hypothesized that bafilomycin A1 
and its analogue, concanamycin A, stimulate a tumor growth factor, hypoxia-inducible 1α 
(HIF-1α) (Zhong et al. 1999). The interaction of bafilomycin with HIF-1α increases with 
hypoxia, causing strong induction of the p21 gene which, in turn, leads to cell cycle 
detection in cancer cells (Lim et al. 2006). 
V-ATPase inhibition has also been shown to trigger apoptosis through caspase-dependent 
and caspase-independent mechanisms (De Milito et al. 2007, Aiko et al. 2002), and 
bafilomycin and concanamycin induce apoptosis in other types of cells, including 
neutrophils (Gottlieb et al. 1995)and osteoclasts (Xu et al. 2003). 
Morimura et al. described the growth-inhibiting effect of apoptosis stimulation in human 
hepatoblastomas using bafilomycin A1. In particular, electron microscopy, morphological 
observations, and flow cytometry showed higher apoptotic cell ratios and diminished cell 
reproduction. Cell growth inhibition in normal liver cells was insignificant (Morimura et 
al. 2008). 
In the case of human gastric cancer cells, Nakashima et al. investigated the mechanism  
of apoptosis induced by bafilomycin A1. Bafilomycin inhibits the growth of MKN-1 
cancer cells through apoptosis. Flow cytometry was used to measure alterations in 
lysosomal pH, which increased in the presence of bafilomycin. Caspase-3 activity was also 
increased by bafilomycin; such findings suggest that bafilomycin A1 induces apoptosis in 
MKN-1 cells mediated by proteases released after lysosomal dysfunction, followed by 
caspase-3 activation of the cytochrome c-independent manner (Nakashima et al. 2003, 
Hishita et al. 2001).  
A study conducted by Wu et al. has shown that bafilomycin A1 suppresses macroautophagy 
by preventing lysosome acidification (Wu et al. 2009). Macroautophagy is a protein 
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degradation pathway that allows increased cell survival under stress and in cancer (Meijer, 
Codogno 2004, Mortimore, Hutson & Surmacz 1983). Macroautophagic inhibition in HT-29, 
HCT-116, and SW1116 colon cancer cells is accompanied by down-regulation of cyclin D 
and E and up-regulation of p21Cip1 and various caspases, causing an antiproliferative effect 
(Wu et al. 2009). 
ancer cells are more likely to express V-ATPase than normal cells, causing abnormalities in 
the acidic microenvironment and affecting cancer cell growth and infiltration significantly 
(Saroussi, Nelson 2008, Cardone, Casavola & Reshkin 2005, Perona, Serrano 1988). 
Moreover, neoplastic cells are more sensitive to bafilomycin A1 than normal cells, a fact that 
may be used in anticancer therapy (Ohta et al. 1996). 
3.3 Chemoresistance  
Resistance to chemotherapy agents is the main reason for treatment failure in patients with 
cancer, and multidrug resistance (MDR) occurs in many types of tumors. The main 
mechanism that gives rise to the MDR phenotype is the overexpression of drug efflux 
transporters such as the P glycoprotein (Pgp) in the plasma membrane (Nielsen, Skovsgaard 
1992) (Figure 3). 
 
 
Fig. 3. Pgp resides in the cell membrane, where it may act to pump toxins out of the cell. The 
painting shows a model of the protein’s structure that is based on its known sequence of 
amino acids. The protein chain is thought to snake back and forth 12 times across the lipid 
bilayer of the membrane forming a 12-sided pore. The pan of the protein outside the cell 
bears sugar chains (purple); two large and nearly identical domains protrude into the cell. 
They include regions (green) that bind the cellular energy-carrying compound ATP, which 
probably provides the energy that drives the efflux (arrows) (Kartner, Ling 1989). 
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Extracellular pH is considerably more acidic in oral squamous cell carcinoma (OSCC), a 
solid tumor, than in normal tissue. This increased acidity interferes with the absorption of 
standard chemotherapy drugs, reducing their effect on tumors (Griffiths 1991, Negendank 
1992). Vacuolar ATPases (V-ATPases) have been reported to be largely responsible for this 
acidic environment (Newell et al. 1993, Yamagata et al. 1998). While a clear association has 
been established between MDR and Pgp expression in some tumors, the mechanism by 
which drug resistance occurs within the multistep process of OSCC has not yet been fully 
elucidated (Tanigawara 2000). OSCC is highly resistant to a wide range of structurally 
different drugs with diverse cytotoxic mechanisms of action (McLeod, Evans 1999). This 
suggests that OSCC may be intrinsically chemoresistant and it is possible that V-ATPases 
play a key role in this resistance (Perez-Sayans et al. 2009). 
3.3.1 Multidrug resistance in OSCC 
As already mentioned, while a clear association has been established between MDR and Pgp 
expression in certain tumors, the mechanism by which drug resistance occurs within the 
multistep process of OSCC has not yet been fully elucidated (Ling 1997). Several genes have 
been implicated in MDR, including MDR1, MRP (multidrug resistance-associated protein), 
GST-π, and DNA topoisomerase II.  
Pgp is encoded by MDR1 and flow cytometry studies have shown increased Pgp levels  
in recurrent OSCCs compared to normal mucosa with oral lesions at different stages of 
tumorigenesis (Jain et al. 1997). These findings were confirmed by immunohistochemical 
staining in a study that compared recurrent tumors with untreated primary oral 
tumors (Chomczynski, Sacchi 2006, Xie et al. 2000). The best known MDR1 gene product 
is Pgp/P-170, which has been implicated in resistance to chemotherapy agents such as 
taxanes, anthracyclines, vinca alkaloids, podophyllotoxins, and camptothecins (Juliano, 
Ling 1976). 
The mechanism by which Pgp-mediated MDR is acquired in head and neck tumors, 
however, is different. Immunohistochemical studies, for example, have revealed high levels 
of Pgp in salivary gland adenocarcinoma (SGA) cell lines but insignificant levels in OSCC 
cell lines (Naramoto et al. 2007). Reverse transcription quantitative polymerase chain 
reaction analysis of MDR1 expression has also revealed increased Pgp levels in different cell 
lines treated with vincristine (alkaloid cancer drug). These results suggest that Pgp-induced 
MDR in OSCC is essentially an acquired phenotype caused by the genetic induction of Pgp 
(Uematsu et al. 2001). 
MRP has been linked to MDR in multidrug-resistant Pgp-negative cells lines in small cell 
lung cancer, cancer of the stomach, bladder, cervix, and prostate, and leukemia (Kim et al. 
1996, Kim et al. 1995, Endo et al. 1996b, Endo et al. 1996a). In head and neck tumors, 
overexpression of MRP1 mRNA has been found in human and murine OSCC and SGA cell 
lines mice treated with vincristine. sugesting the theory of Pgp- and MRP-independent 
MDR in OSCC. 
Overexpression of the isozyme GST-π is often associated with malignant transformation 
and/or MDR (Ruzza et al. 2009). GST-π is responsible for detoxifying xenobiotics such as 
carboplatin (used in chemotherapy) and elevated levels of this enzyme cause treatment 
resistance (Engel et al. 2005, Koshiyama et al. 2001). Whether or not this is also the case in 
OSCC, however, is a matter of debate. In a study by Chen et al (Chen, Lin 1997), GST-π 
levels increased with increased severity of oral epithelial dysplasia in line with the 
development of OSCC. The immunohistochemical expression of placental GST-π has been 
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studied in the oral epithelium of premalignant and malignant oral lesions, and has indeed 
been proposed as a good marker for premalignant lesions and tumors (Zhang, Xiao & 
Priddy 1994). Another study, however, that analyzed GST-π levels using enzyme-linked 
immunoassay failed to find a significant relationship between GST-π and TNM stage (Oude 
Ophuis et al. 1998). Finally, in a study that analyzed GST-π expression using Northern blot 
analysis and gene amplification with Southern blot analysis, Wang et al (Wang et al. 1997) 
concluded that the amplification of the GST-π gene was not critically related to the 
overexpression of GST-π mRNA. Furthermore, they found no relationship between GST-π 
mRNA overexpression and tumor size, neck nodal status, or patient survival. 
The downregulation of topoisomerase II—an enzyme that breaks and rejoins double-
stranded DNA in the interconversion of different topological forms of DNA—has also been 
associated with MDR (Deffie, Batra & Goldenberg 1989, Shi et al. 2008). 
The mechanisms underlying MDR response are less clear in OSCC than in other types of 
tumors (Yajima et al. 2009). MDR holds challenges for both researchers and the 
pharmaceutical industry. Accordingly, efforts are being made on all sides to find anticancer 
compounds characterized not only by high tolerability and oral bioavailability but also by 
the ability to overcome the problem of drug resistance. OSCC is highly resistant to a wide 
range of structurally different drugs with different cytotoxic mechanisms of action (McLeod, 
Evans 1999). This suggests that OSCC may be intrinsically chemoresistant, with other 
molecules, including V-ATPases, playing an important role (Perez-Sayans et al. 2009). 
3.3.2 The role of v-ATPases in multidrug resistance 
It has been demonstrated that hypoxia and acidity contribute to the transition from benign 
to malignant growth via the selection of tumor cells capable of surviving in an acidic, 
oxygen-deprived environment. Acidity, for example, has been associated with 
chemotherapy resistance (Raghunand et al. 2001), proliferation (Morita et al. 1992), and 
metastatic behavior (Martinez-Zaguilan et al. 1996). Indeed, alteration of the pH gradient 
between the extracellular environment and the cell cytoplasm has been suggested as a 
possible mechanism of resistance to cytotoxic drugs (De Milito, Fais 2005a) (Figure 4). 
The alteration of cytosolic pH also plays an important role in drug resistance in 
chemotherapy. Extracellular pH in solid tumors is significantly more acidic than in normal 
tissue. This increased acidity interferes with the absorption of basic chemotherapy drugs, 
reducing their effect on tumors (Griffiths 1991, Negendank 1992). Martínez-Zaguilán et al., 
found that unlike chemoresistant cells, chemosensitive cells did not recover from acid 
load (Martínez-Zaguilán et al. 1999). Becellli et al (Becelli et al. 2007) found that reversed pH 
gradient was directly related to drug resistance.  
Anaerobic metabolism is an important determinant of tumor acidity that allows the 
selection of cells capable of surviving in a hypoxic-anaerobic environment via the synthesis 
of lactate. A complex system appears to regulate pH homeostasis in mammal cells, and it 
seems as if malignant tumor cells are capable of exploiting some of these mechanisms to 
protect themselves from the acidic environment, while maintaining levels of acidity that are 
poorly tolerated by normal or more differentiated cells (De Milito, Fais 2005b). 
Recent studies have suggested that V-ATPases, which secrete protons through the plasma 
membrane, may play a key role in the acidification of the tumor environment (Perez-Sayans 
et al. 2009). Several human tumor cells are characterized by increased V-ATPase expression 
and activity (Perez-Sayans et al. 2010), and pretreatment with proton pump inhibitors (PPIs) 
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has been found to sensitize tumor cell lines to the effect of different chemotherapy drugs (De 
Milito, Fais 2005a, Luciani et al. 2004, De Milito, Fais 2005b, Sennoune, Luo & Martinez-
Zaguilan 2004). The effectiveness of the drug transport mechanism appears to be 
comparable to that of drug efflux pumps such as Pgp, although vesicle acid exchange (above 
all in vesicles that have an active H+/cation exchange system) may be an important factor in 
drug resistance, and particularly in cells that do not overexpress Pgp-type efflux pumps in 
the plasma membrane (Raghunand et al. 1999).  
Murakami et al (Murakami et al. 2001) found cisplatin-resistant tumors to contain elevated 
levels of all V-ATPase subunits but levels of ATP6C were particularly. They also found 
significantly higher levels of cellular pH in cisplatin-resistant tumor cells than in cells 
sensitive to vincristine and etoposide. In a later study, however, Zhang et al (Zhang et al. 
2006) identified 38 overexpressed genes and 25 underexpressed genes in cisplatin-resistant 
OSCC. Torigoe et al (Torigoe et al. 2002) showed that treatment with anticancer agents 
increased ATP6L (c subunit). Interfering RNA targeting the c subunit has also been found to 
improve drug resistance in breast cancer cells (You et al. 2009). 
4. Conclusions 
The above findings suggest that the induced expression of V-ATPases in MDR is an anti-
apoptotic defence and that the combined use of PPIs or V-ATPase inhibitors and low 
chemotherapy doses might be a possible treatment target (Torigoe et al. 2002). We believe 
that the future of these molecules in cancer treatment involves measuring the 
overexpression of specific V-ATPase subunits in tumors to be treated and then using 
inhibitors specific for the subunits being expressed (Perez-Sayans et al. 2009, Perez-Sayans et 
al. 2010). This will allow clinicians to provide more specific treatment, while also 
minimizing adverse effects. 
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